Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
Moodys
McKinsey
Mallinckrodt
Colorcon

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,943,621

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,943,621 protect, and when does it expire?

Patent 7,943,621 protects VRAYLAR and is included in one NDA.

This patent has thirty-seven patent family members in thirty-one countries.

Summary for Patent: 7,943,621
Title:Salts of piperazine compounds as D.sub.3/D.sub.2 antagonists
Abstract: The present invention relates to novel monohydrochloride, dihydrochloride, monohydrobromide, maleate and methanesulphonate salts of trans 4-{2-[4-(2,3-dichlorophenyl)-piperazine-1-yl]-ethyl}-N,N-dimethylca- rbamoyl-cyclohexylamine and/or their hydrates and/or solvates. Moreover, the invention relates to the process for preparing the salts and their hydrates and/or solvates, to their use in the treatment and/or prevention of conditions which require modulation of dopamine receptor and to pharmaceutical compositions containing them.
Inventor(s): Czibula; Laszlo (Budapest, HU), Sebok; Ferenc (Mezokovacshaza, HU), Greiner; Istvan (Budapest, HU), Domany; Gyorgy (Obanya, HU), Csongor; Eva Againe (Budapest, HU)
Assignee: Richter Gedeon Nyrt. (Budapest, HU)
Application Number:12/118,437
Patent Claim Types:
see list of patent claims
Compound; Process; Composition;

Drugs Protected by US Patent 7,943,621

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan Sales Llc VRAYLAR cariprazine hydrochloride CAPSULE;ORAL 204370-001 Sep 17, 2015 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Allergan Sales Llc VRAYLAR cariprazine hydrochloride CAPSULE;ORAL 204370-002 Sep 17, 2015 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Allergan Sales Llc VRAYLAR cariprazine hydrochloride CAPSULE;ORAL 204370-003 Sep 17, 2015 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Allergan Sales Llc VRAYLAR cariprazine hydrochloride CAPSULE;ORAL 204370-004 Sep 17, 2015 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,943,621

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2008249772   Start Trial
Brazil PI0811199   Start Trial
Canada 2684404   Start Trial
China 101679315   Start Trial
Colombia 6241112   Start Trial
Cyprus 1119076   Start Trial
Denmark 2155696   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Harvard Business School
AstraZeneca
Dow
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.